|
|
|
| Relationship between the expression levels of serum lncRNA-MALAT-1 and miR-143 and the clinical features and prognosis of acute myeloid leukemia |
| HE Xu HU Yinshan XU Sunqiu YANG Kun MA Chunrong |
| Department of Hematopathology, the Second Clinical Medical School of North Sichuan Medical University Nanchong Central Hospital, Sichuan Province, Nanchong 637000, China |
|
|
|
Abstract Objective To investigate the relationship between the expression levels of serum long-stranded non-coding RNA (lncRNA)-lung adenocarcinoma metastasis-associated transcript 1 (MALAT-1) and microRNA-143 (miR-143) and the clinical features and prognosis of acute myeloid leukemia. Methods Eighty-seven patients with acute myelogenous leukemia(AML） admitted to the Department of Hematology of Nanchong Central Hospital (hereinafter referred to as “our hospital”) from January 2017 to April 2019 were selected as the AML group, and 32 healthy patients who underwent physical examination in our hospital during the same period were selected as the control group. The expressions of serum lncRNA-MALAT-1 and miR-143 were detected by qPCR. The correlation between the two expressions and the clinical features of AML was analyzed. According to the mean expression values of serum lncRNA-MALAT-1 and miR-143, patients were divided into high and low expression groups. Kaplan-Meier method was used to draw the survival curve of AML patients. Results Serum lncRNA-MALAT-1 expression in the AML group was higher than that in the control group, and miR-143 expression was lower than that in the control group (P＜0.01). Pearson’s correlation coefficient showed that serum lncRNA-MALAT-1 was negatively correlated with miR-143 expression in the AML group (r = -0.709, P＜0.01). Comparison of serum lncRNA-MALAT-1 and miR-143 expression in AML patients with different white blood cell counts, bone marrow primitive cell ratios, and prognostic risk stratification showed statistically significant differences (P＜0.05). Comparison of survival curves between the high expression group and the low expression group of lncRNA- MALAT-1 showed a statistically significant difference (P＜0.05); Comparison of survival curves between the high expression group and the low expression group of miRNA showed a statistically significant difference overall survival rate was higher in the miR-143 high expression group than in the miR-143 low expression group (P＜0.05). Conclusion High expression of serum lncRNA-MALAT-1 and low expression of miR-143 in AML patients is associated with leukocyte count, bone marrow primitive cell ratio, prognostic risk stratification and prognosis.
|
|
|
|
|
|
[1] 中国抗癌协会血液肿瘤专业委员会，中华医学会血液学分会白血病淋巴瘤学组.中国成人急性淋巴细胞白血病诊断与治疗指南（2021年版）[J].中华血液学杂志，2021， 42（9）：705-716.
[2] 何雨晨，徐英英，葛繁梅.长链非编码RNA在急性髓系白血病发病中作用机制的研究进展[J].山东医药，2020， 60（3）：94-97.
[3] Esa E，Hashim AK，Mohamed EHM，et al. Construction of a microRNA-mRNA Regulatory Network in De Novo Cytogenetically Normal Acute Myeloid Leukemia Patients [J]. Genet Test Mol Biomarkers，2021，25（3）：199-210.
[4] Faruk EM，Sabry D，Morsi AA，et al. The anti-tumour effect of induced pluripotent stem cells against submandibular gland carcinoma in rats is achieved via modulation of the apoptotic response and the expression of Sirt-1，TGF-β，and MALAT-1 in cancer cells [J]. Mol Cell Biochem，2022， 477（1）：53-65.
[5] 范荣辉，徐子寒，慕生枝，等.MALAT1通过靶向miR-204调控TFAM表达对皮肤鳞状细胞癌增殖及凋亡的影响[J].兰州大学学报（医学版），2022，48（2）：9-15.
[6] Ding C，Shi T，Wu G，et al. The anti-cancer role of microRNA-143 in papillary thyroid carcinoma by targeting high mobility group AT-hook 2 [J]. Bioengineered，2022，13（3）：6629-6640.
[7] 王秋宇，姜平，朱军义，等.miR-143介导ADAM17基因对子宫内膜癌细胞生物活性的作用机制[J].解剖学杂志，2021，44（5）：411-415.
[8] D?觟hner H，Estey EH，Amadori S，et al. Diagnosis and management of acute myeloid leukemia in adults： recommendations from an international expert panel，on behalf of the European Leukemia Net [J]. Blood，2010，115（3）：453-474.
[9] 中华医学会血液学分会.成人急性髓系白血病（非急性早幼粒细胞白血病）中国诊疗指南（2011年版）[J].中华血液学杂志，2011，32（11）：804-807.
[10] Heuser M，Ofran Y，Boissel N，et al. Acute myeloid leukaemia in adult patients： ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up [J]. Ann Oncol，2020， 31（6）：697-712.
[11] 中华医学会血液学分会白血病淋巴瘤学组.中国复发难治性急性髓系白血病诊疗指南（2021年版）[J].中华血液学杂志，2021，42（8）：624-627.
[12] Dai E，Zhu Z，Wahed S，et al. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy[J]. Mol Cancer，2021，20（1）：171.
[13] 杨万斌，徐燕，卓士铉，等.长链非编码RNA相关表观遗传修饰在癌症中的进展[J].中国生物工程杂志，2021， 41（8）：59-66.
[14] 皮益苑，周爽，简鸣，等.LncRNA中miRNA海绵活性与肿瘤的研究进展[J].中南医学科学杂志，2019，47（3）：230-234.
[15] 茆艳，周国平.长链非编码RNA MALAT1与肿瘤性疾病相关性的研究进展[J].现代肿瘤医学，2020，28（5）：862-866.
[16] Ferri C，Di Biase A，Bocchetti M，et al. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer [J]. J Exp Clin Cancer Res，2022，41（1）：20.
[17] 阿小英，郭桂兰，任玉环，等.LncRNA MALAT1靶向miR124-3p/STAT3对宫颈癌细胞增殖和侵袭的影响[J].中国妇产科临床杂志，2021，22（3）：267-269.
[18] Li S，Wang Q，Qiang Q，et al. Sp1-mediated transcriptional regulation of MALAT1 plays a critical role in tumor [J]. J Cancer Res Clin Oncol，2015，141（11）：1909-1920.
[19] Sheng XF，Hong LL，Li H，et al. Long non-coding RNA MALAT1 modulate cell migration，proliferation and apoptosis by sponging microRNA-146a to regulate CXCR4 expression in acute myeloid leukemia [J]. Hematology，2021， 26（1）：43-52.
[20] Konishi H，Sato H，Takahashi K，et al. Tumor-Progressive Mechanisms Mediating miRNA-Protein Interaction [J]. Int J Mol Sci，2021，22（22）：12303.
[21] 郭春宣，钟纯正，李琦，等.循环miR-143和miR-182预测急性缺血性卒中患者转归的价值[J].国际脑血管病杂志，2021，29（3）：184-188.
[22] Xu J，Li X，Zhang P，et al. miR-143-5p suppresses breast cancer progression by targeting the HIF-1α-related GLUT1 pathway [J]. Oncol Lett，2022，23（5）：147.
[23] Han X，Liu D，Zhou Y，et al. The negative feedback between miR-143 and DNMT3A regulates cisplatin resistance in ovarian cancer [J]. Cell Biol Int，2021，45（1）：227-237.
[24] Chen J，Gong J. CircMMP11 overexpression predicts the poor survival of non-small cell lung cancer and downregulates miR-143 through methylation to suppress cell proliferation [J]. J Cardiothorac Surg，2021，16（1）：327.
[25] 姚金晓，杨如玉，马海龙，等.miR-143通过靶向调控HK2的表达抑制急性髓系白血病细胞迁移和侵袭的分子机制[J].中国老年学杂志，2019，39（6）：1397-1401. |
|
|
|
